Hemoglobin vesicles ameriolate allograft airway rejection

• Project/Area Number: 24791470
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Thoracic surgery
• Research Institution: Keio University
• Principal Investigator: KASEDA Kaoru 慶應義塾大学, 医学部, 助教 (70624435)
• Project Period (FY): 2012-04-01 – 2014-03-31
• Project Status: Completed (Fiscal Year 2013)
• Budget Amount: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000); Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000); Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
• Keywords: 肺移植

Research Abstract

Acute rejection after lung transplantation is the main risk factor for the development of bronchiolitis obliterans (BO). Hemoglobin-vesicles (HbV) have been developed for use as artificial oxygen carriers and this can provide anti-inflammatory effects and may serve to limit tissue injury in airway transplant. Here, we tested the ability of HbV to prevent airway rejection. Tracheal grafts from BALB/c or C57BL/6 were transplanted to C57BL/6 recipients. Experimental groups were treated with HbV. Histopathological evaluation of luminal obliteration was blindly reviewed. Immunohistochemistry and real-time RT-PCR analyses were performed. Allografts treated with HbV revealed a reduction of thickening in epithelial and subepithelial airway layers at day 7 in orthotopic trachea transplantation model compared with allografts treated with vehicle. There was also a concordant decrease in CD3+ lymphocytes and macrophages in HbV treated allografts.

Research Products

• [Journal Article] Carbon monoxide releasing molecule attenuates airway allograft rejection (2014)
  • Author(s): Takashi Ohtsuka, Kaoru Kaseda
  • Journal Title: Transplant International Volume: 印刷中 Issue: 7 Pages: 741-747
  • DOI: 10.1111/tri.12314
  • Peer Reviewed